Prevention of urinary bladder cancer: The interface between experimental and human studies

Asian Pacific Journal of Cancer Prevention

Volumn 1, Issue 1, 2000, Pages 15-33

  Fukushima, Shoji ^a   Wanibuchi, Hideki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857941176     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (251)

1. Abdel-Tawab GA, Aboul-Azm T, Ebid SA, et al (1986). The correlation between certain tryptophan metabolites and the N-nitrosamine conetent in the urine of bilharzial bladder patients. J Urol, 135, 826-30.
2. Abdel-Mohsen MA. Hassan AA, et al (1999). Biomonitoring of n-nitroso compounds, nitrite and nitrate in the urine of Egyptian bladder cancer patients with or without Schistosoma haematobium infection. Int J Cancer, 82, 789-94.
3. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa HM, Au WW (1998). GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prevent, 22, 129-38.
4. Aladnani MS. Saleh KM (1983) Schistosomiasis and bladder carcinoma in Southern Iraq. J Trop Med Hyg, 86, 93-7.
5. Al-Abadi H, Nagel R, Neuhaus P (1998). Immunohistochemical detection of p53 protein in transitional cell carcinoma of the bladder in correlation to DNA ploidy and pathohistological stage and grade. Cancer Detect Prevent, 22, 43-50,.
6. Al-Shukri S, Alwan MH, Nayef M, Rahman AA (1987). Bilharsiasis in malignant tumours of the urinary bladder. Br J Urol, 59, 59-62.
7. Armstrong B, Doll R (1975). Environmental factors and cancer incidence and mortality in different countries with special reference to dietary practises. Int J Cancer, 15, 617-31.
8. Auerbach O, Garfinkel L (1989). Histologic changes in the urinary bladder in relation to cigarette smoking and use of artificial sweeteners. Cancer, 64, 983-7.
9. Babaya K, Izumi K, Ozono S, et al (1983) Capability of urinary components to enhance ornithine decarboxylase activity and promote urothelial tumorigenicity. Cancer Res, 43, 1774-82.
10. Badawi AF, Cooper DP, Mostafa MH, et al (1993). Promutagenic methylation damage in liver DNA of mice infected with Schistosoma mansoni. Carcinogenesis, 14, 653-7.
11. Badawi AF, Mostafa MH, Boul-Azm T, et al (1992a). Promutagenic methylation damage in bladder DNA from patients with bladder cancer associated with schistosomiasis and from normal individuals. Carcinogenesis, 13, 877-81.
12. Badawi AF, Mostafa MH, O'Connor, et al (1992b). Involvement of alkylating agents in schistosomiasis - associated bladder cancer: the possible basic mechanismsof induction. Cancer Letts, 63, 171-88.
13. Badawi AF, Mostafa MH, Probert A, O'Connor PJ (1995). Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur J Cancer Prev, 4, 45-59.
14. Barbone F, Francheschi S, Talamin R, et al (1994). Occupation and bladder cancer in Pordernone (north-east Italy): a casecontrol study. Int J Epidemiol, 23, 58-65.
15. Baud E, Catilina P, Bignon YJ (1999). p16 involvement in primary bladder tumors: analysis of deletions and mutations. Int J Oncol, 14, 441-5.
16. Bedwani R, El-Khwsky F, Renganathan E, et al (1997). Epidemiology of bladder cancer in Alexandria, Egypt: tobacco smoking. Int J Cancer, 73, 64-7.
17. Bhagwandeen SB (1976). Schistosomiasis and carcinoma of the bladder in Zambia. S Afr Med J 50, 1616-20.
18. Bi W, Haye RB, Feng P, et al (1992). Mortality and incidence of bladder cancer in benzidine-exposed workers in China. Am J Ind Med, 21, 481-9.
19. Bintinx F, Wauters H (1997). The diagnostic value of macrosopic haematuria in diagnosing urological cancers: a metanalysis. Fam Pract, 14, 63-8.
20. Bos J L Åi(1989). ras oncogenes in human cancer: a review. Cancer Res, 49, 4682-9.
21. Brawn PN (1982). The origin of invasive carcinoma of the bladder. Cancer, 50, 515-9.
22. Bringuier PP, Tamimi Y, Schuuring E, Schalken J (1996). Overexpression of cycin D1 and EMS1 in bladder tumors; relationship with chromosome 11q13 amplification. Oncogene, 12, 1747-53.
23. Brown JLÅA Kitchin KT (1996). Arsenite, but not cadmium, induces ornithine decarboxylase and heme oxygenase activity in rat liver: relevance to arsenic carcinogenesis. Cancer Lett, 98, 227-31.
24. Bruemmer B, White E, Vaughan TL, Cheney CL (1996). Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol, 144, 485-95.
25. Bryan GT, Erturk E, Yoshida O (1970). Production of urinary bladder carcinomas in mice by sodium saccharine. Science, 168, 1238-40.
26. Burch JD, Rohan TE, Howe GR, et al (1989). Risk of bladder cancer by source and type of tobacco exposure. A casecontrol study. Int J Cancer, 44, 622-8.
27. Cartwright RA, Adib R, et al (1993). Cigarette smoking and bladder cancer: an epidemiological inquiry in West Yorkshire. J Epidemiol Coummunity Health, 37, 256-63.
28. Cartwright RA, Glashan RW, Rogers HJ, et al (1982). Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2, 842-5.
29. Case RAM, Hosker ME, McDonald DB, Pearson JT (1954). Tumours of the urinary bladder in workmen in the manufacture and use of certain dyestuff intermediates in the Britsih Chemical Industry, Part I. Br J Indust Med, 11, 75-104.
30. Cheever AW, Kuntz RE, Moore JA, Huang TC (1988). Pathology of Schistosoma haematobium infection in the Capuchin monkey (Cebus appela). Trans R Soc Trop Med Hyg, 82, 107-11.
31. Chen C-J, Chuang Y-C, Lin T-M, et al (1985). Malignant neoplasms among residents of a blackfoot disease endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res, 45, 5895-9.
32. Chen MG, Mott KE (1989). Progress in the assessment of morbidity due to Schistosoma haematobium infections: a review of the recent literature. Trop Dis Bull, 48, 2643-8.
33. Chen T, Na Y, Wanibuchi H, et al (1999). Loss of heterozygosity in (LewisxF344)F1 rat urinary bladder tumors induced with N-butyl-N-(4-hydroxybutyl)nitrosamine followed by dimethylarsinic acid or sodium L-ascorbate. Jpn J Cancer Res, 90, 818-23.
34. Chen T, Yamamoto S, Gen H, et al., (1998). Infrequent involvement of microsatellite instability in urinary bladder carcinomas of the NON/Shi mouse treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Lett, 123, 41-5.
35. Chow W-H, Lindblad P, Gridley G, et al (1997) Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst, 89, 1453-7.
36. Christie JD, Crous D, Kelada AS, et al (1986). Patterns of Schistosoma haematobium egg distribution in the human urinary tract. III. Cancerous lower urinary tracts. Am J Trop Med Hyg, 35, 759-64.
37. Chyou PH, Nomura AM, Stemmermann GN (1993). A prospective study of diet, smoking and lower urinary tract cancer. Ann Epidemiol, 3, 211-6.
38. Claude J, Kunze E, Frentzel-Beyme R, et al (1986). Life-style and occupational risk factors in cancer of the lower urinary tract. Am J Epidemiol, 124, 578-89.
39. Clavel J, Cordier S, Boccon-Gibod L, Hemon D (1989). Tobacco and bladder cancer in males. Increased risk for inhalers and smokers of black tobacco. Int J Cancer, 44, 605-10.
40. Cohen SM, Arai M, Jacobs JB, Friedell GH (1979). Promoting effect of saccharin and D, L-tryptophan in urinary bladder carcinogenesis. Cancer Res, 39, 1207-17.
41. Cohen SM, Ellwein LB, Okamura T, (1991). Comparative bladder tumor promoting activity of sodium saccharin, sodium ascorbate related acids, and calcium salts in rats. Cancer Res, 51, 1766-77.
42. Cohen SM, Garland EM, John M St, Okamura T, Smith RA (1992). Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res, 52, 3577-81.
43. Cordon-Cardo C, Wartinger D, Petrylak D, et al (1992). Altered expression of retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst, 84, 1251-6.
44. Curtis RE, Boice JDJr, Kleinerman RA et al (1985). Summary: Multiple cancers in Connecticut, 1935-1982. Natl Cancer Inst Monogr 68: 219-42.
45. De Stefani E, Correa P, Fierro L, et al (1991). Black tobacco, maté and bladder cancer: a case-control study from Uruguay. Cancer, 67, 536-40.
46. Dolin PJ, Darby SC, Beral V (1994). Paraplegia and squamous cell carcinoma of the bladder in young women: findings from a case-control study. Brit J Cancer, 70, 167-8.
47. Droller MJ, Gomolka D (1984). Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. J Urol, 131, 1212-7.
48. Druckrey H, Preussman R, Ivankovic S, et al (1964). Selektive Erzeugung von Blasenkrebs an Ratten durch Dibutyl-und N-Butyl-N-butanol(4)nitrosamine. Z Krebsforsch, 66, 280-90.
49. Elcock M, Morgan RW (1993) Update on artificial sweeteners and bladder cancer. Regul Toxicol Pharmacol, 17, 35-43.
50. Elem B, Purohit T (1983). Carcinoma of the urinary bladder in Zambia: a quantitiative estimate of Schistosoma haematobium infection. Br J Urol, 55, 275-8.
51. Ellwein LB, Cohen SM (1990). The health risks of saccharin revisited. Crit Rev Toxicol, 20, 311-24.
52. El-Merzabani MM, El-Aaser AA, Zakhary NI (1979). A study on the etiological factors of bilharzial bladder cancer in Egypt, 1. Nitrosamines and their precursors in urine. Eur J Cancer, 15, 287-91.
53. El-Morsi B, Sherif M, El-Raziki ES (1974). Experimental bilharzial squamous metaplasia of the urinary bladder in hamsters. Eur J Cancer, 11, 199-201.
54. Endo G, Kuroda, K Okamoto A, Horiguchi S. (1992) Dimethylarsinic acid induces tetraploidy in Chinese hamster cells. Bull Environ Contam Toxicol, 48, 131-7.
55. Floyd RA (1990). The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis, 11, 1447-50.
56. Fortuny J. Kogevinas M. Chang-Claude J, et al (1999). Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. Int J Cancer, 80, 44-6.
57. Fraumeni JF Jr, Thoman LB (1967). Malignant bladder tumors in a man and his three sons. JAMA, 201, 507-9.
58. Friedman GD, Carroll PR, Cattolica EV, Hiatt RA (1996). Can hematuria be a predictor as well as a symptom or sign of bladder cancer?. Cancer Epidemiol Biomarkers Prevent, 5, 993-6.
59. Fujimoto, K., Yamada, Y., Okajima, E, et al (1992). Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res, 52, 1393-8.
60. Fukagai T, Ishihara M, Funabashi K, Naitoh Y, Maruyama K (1996).Multiple primary malignant neoplasms associated with genitourinary cancer. [in Japanese] Acta Urol Japon, 42, 181-5.
61. Fukushima S (1991). Modification of tumor development in the urinary bladder. In 'Modification of Tumor Development in Rodents', Ito N, Sugano H (Eds). Prog Exp Tumor Res, 33, 154-74.
62. Fukushima S, Imaida K, Sakata T, Okamura T, Shibata M, Ito N (1983). Promoting effects of sodium L-ascorbate on twostage urinary bladder carcinogenesis in rats. Cancer Res, 43, 4454-7.
63. Fukushima S, Shibata M, Shirai T, Tamano S, Ito N (1986). Roles of urinary sodium ion concentration and pH in promotion by ascorbic acid of urinary bladder carcinogenesis in rats. Cancer Res, 46, 1623-6.
64. Fukushima S, Imaida K, Shibata M-A, et al (1988). L-ascorbic acid amplification of second-stage bladder carcinogenesis promotion by NaHCO3. Cancer Res, 48, 6317-20.
65. Fukushima S, Shibata M-A, Shirai T, et al (1987). Promotion by L-ascorbic acid of urinary bladder carcinogenesis in rats under conditions of increased urinary K ion concentration and pH. Cancer Res, 47, 4821-4.
66. Fukushima S, Shibata M-A, Tamano S, et al (1987). Aging and urinary bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. J Natl Cancer Inst, 79, 263-7.
67. Fukushima S, Tanaka H, Asakawa E, et al (1992). Carcinogenicity of uracil, a nongenotoxic chemical, in rats and mice and its rationale. Cancer Res, 52, 1675-80.
68. Fukushima S, Murasaki G, Hirose M, et al (1982). Histopathological analysis of preneoplastic changes during N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats. Acta Pathol Jpn, 32, 243-50.
69. Fukushima S, Wanibuchi H, Yamamoto S (1999). Testing, predicting and interpreting carcinogenicity. III Interpreting carcinogenicity. B Organs with high animal and high human cancer rates. Urinary bladder. ?
70. Gelfand M, Weinberg RW, Castle WM (1967). Relation between carcinoma of the bladder and infestation with Schistosoma haematobium. Lancet, i, 1249-51.
71. Gilbert HA, Logan JL, Kagan AR, et al (1978). The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histological grading. J Urol, 119, 488-92.
72. Giroldi LA. Bringuier PP. Shimazui T. Jansen K. Schalken JA (1999). Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. Int J Cancer, 82, 70-6
73. Gonzales CA, Errezola M, Izarzugaza I, et al (1991). Urinary infection, renal lithiasis and bladder cancer in Spain. Eur J Cancer, 27, 498-500.
74. Gonzalez-Zulueta, M., Ruppert, J. M., Tokino, K., et al (1993). Microsatellite instability in bladder cancer. Cancer Res, 53, 5620-3.
75. Gordon GB, Helzlsouer KJ, Comstock GW (1991). Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res, 51, 1366-9.
76. Gremy F, Momas I, Daures P (1993). Risk factors in bladder cancer: a case-control study in the Department of Harault, France. Bull Acad Natl Med, 177, 47-60.
77. Grubbs CJ, Juliana MM, Eto I, et al (1993). Chemoprevention by indomethacin of n-butyl-n-(4-hydroxybutyl)-nitrosamineinduced urinary bladder tumors. Anticancer Res, 13, 33-36.
78. Habel LA. Bull SA. Friedman GD (1998). Barbiturates, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prevent, 7, 1049-50.
79. Hasegawa R, Greenfield RE, Murasaki G, et al (1985). Initiation of urinary bladder carcinogenesis by freeze ulceration with sodium saccharin promotion. Cancer Res 45: 1469-73
80. Hashimoto Y, Iiyoshi M, Okada M (1974). Rapid and selective induction of urinary bladder cancer in rats with N-ethyl-N-(4-hydroxybutyl)nitrosamine and by its principal urinary metabolite. Gann, 65, 565-6.
81. Hartge P, Silverman D, et al (1987). Changing cigarette habits and bladder cancer risk. J Natl Cancer Inst, 78, 1119-25.
82. Hemstreet GP 3rd. Rao J. Hurst RE. et al (1999). Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. Cancer Detect Prevent, 23, 163-71.
83. Heney NM, Ahmed S, Flanagan MJ, et al (983). Superficial bladder cancer: progression and recurrence. J Urol, 130, 1083-6.
84. Heney NM, Nocks BN, Daly JJ, et al (1982). Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol, 54, 152-7.
85. Herr HW, Laudone VP, Whitmore WF (1987). An overview of intravesical therapy for syperficial bladder tumors. J Urol, 138, 1363-7.
86. Hiatt RA, Ordonez JD (1994). Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prevent 3: 439-43.
87. Hicks RM, James C, Webbe G (1980). Effect of Schistosoma haematobium on the development of urothelial neoplasia in the baboon, Br J Cancer, 42, 730-55.
88. Hicks RM, Wakefield JStJ (1972). Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea I. Histology. Chem Biol Interact, 5, 139-52.
89. Hicks RM, Wakefield J, Chowaniel J (1975). Evaluation of a new model to detect bladder carcinogens or co-carcinogens; results obtained with saccharin, cyclamate, and cyclophosphamide. Chem Biol Interact, 11, 225-33.
90. Hirose M, Yamaguchi T, Kimoto N, et al (1998). Strong promoting activity of phenylethyl isothiocyanate and benzyl isothiocyanate on urinary bladder carcinogenesis in F344 male rats. Int J Cancer, 77, 773-7.
91. Homma Y, Kakizoe T, Samma S, Oyasu R (1987). Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by a-difluoromethylornithine. Cancer Res, 47, 6176-9.
92. Hopenhayn-Rich C, Biggs ML, Fuchs A, et al (1996). Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology, 7, 117-24.
93. Hultengren N, Lagergren C, Ljungquist A (1968). Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand, 130, 314-20.
94. IARC Monographs on the evaluation of carcinogenic risk of chemicals to humans: Some non-nutritive sweetening agents. Vol. 22. Lyon, France, IARC, 1980.
95. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Overall evaluations of carcinogenicity: An updating of IARC monographs vol 1-24 (suppl 7), Lyon, France, IARC 1987.
96. IARC Monographs Suppl 6, Genetic and related effects. Vol. 1. to 42. An updating of selected IARC Monographs. 1987; 113-115.
97. IARC Monographs on the evaluation of the carcinogenic risks of chemicals to humans: Coffee, tea, mate, methylxanthines and methylglyoxal. Vol. 51. Lyon, France, IARC, 1991.
98. Imaida K, Fukushima S, Shirai T, et al (1983). Promoting activities of butylated hydroxyanisole and butylated hydroxytoluene on 2-stage urinary bladder carcinogenesis and inhibition of É¡-glutamyltranspeptidase-positive foci development in the liver of rats. Carcinogenesis; 4, 895-9.
99. Isaka H, Yoshii H, Otuji A, et al (1979). Tumors of Sprague-Dawley rats induced by long-term feeding of phenacetin. Gann, 70, 29-36.
100. Ishcovish J, Castelletto R, et al (1987). Tobacco smoking, occupational exposure and bladder cancer in Argentina. Int J Cancer, 40, 734-40.
101. Ishikawa J, Xu HJ, Hu SJ, et al (1991). Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res, 51, 5736-43.
102. Ito N, Fukushima S (1989). Promotion of urinary bladder carcinogenesis in experimental animals. Exp Pathol, 36, 1-15.
103. Ito N, Hiasa Y, Tamai A, Okajima E, Kitamura H (1969). Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gann, 60, 401-10.
104. Ito N, Makiura S, Yokota Y, et al (1971). Effect of unilateral ureter ligation on development of tumors in the urinary system of rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Gann, 62, 359-65.
105. Iwata H, Yamamoto S, Yano Y, Ohtani S, Fukushima S (1997). Dose-dependent amplification by L-ascorbic acid of NaHCO3 promotion of rat urinary bladder carcinogenesis. Toxicol Pathol, 25, 284-90.
106. Jacobson MF. Farber E. Clapp R (1998). Re: Long-term feeding of sodium saccharin to nonhuman primates: implications for urinary tract cancer. J Natl Cancer Inst, 90, 934-6.
107. Jensen OM, Wahrendorf J, et al (1987) The Copenhagen casecontrol study of bladder cancder: role of smoking in invasive bladder tumours. J Epidemiol Community Health, 41, 734-40.
108. Johansson SL (1981). Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int J Cancer, 27, 521-9.
109. Johansson SL, Radio SJ, Saidi J, Sakata T (1989). The effects of acetaminophen, antipyrine and phenacetin on rat urothelial cell proliferation. Carcinogenesis, 10, 105-11.
110. Kantor AF, Hartge P, Hoover RN, Fraumeni JFJr (1988). Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res, 48, 3853-5.
111. Kantor AF, Hartge P, Hoover RN, et al (1984). Urinary tract infection and risk of bladder cancer. Am J Epidemiol, 119, 510-5.
112. Kaye KW, Lange PH (1982). Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol, 128, 31-3.
113. Khan MA, Travis LB, Lynch CF, et al (1998). p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prevent, 7, 397-403.
114. King WD, Marrett LD (1996) Case-control study of bladder cancer and chlorination by-products in treated water (Ontario, Canada). Cancer Causes Control, 7, 596-604.
115. Kitano M, Mori S, Chen T, Murai T, Fukushima S (1995) Lack of promoting effects of alpha-linolenic, linoleic or palmitic acid on urinary bladder carcinogenesis in rats. JpnJ Cancer Res, 86, 530-4.
116. Kjaer SK, Knudsen JB, Sorensen BL, Moller Jensen O (1989). The Copenhagen case-control study of bladder cancer. V. Review of the role of urinary-tract infection. Acta Oncol, 28, 631-6.
117. Klän R, Knispel HH, Meier T (1993). Acetylsalicyclic acid inhibition of N-butyl(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol, 119, 482-5.
118. Koriatim MM, Metwalli NE, Atta MA, El-Sadr AA (1995). Changing age and pathological types of schistosomaassociated bladder carcinoma. J Urol, 154, 1714-6.
119. Koyama K, Furukawa Y, Tanaka H (1995). Multiple primary malignant neoplasms in urologic patients. Scand J Urol Nephrol 29: 483-90.
120. Knowles MA, Williamson M (1993). Mutation of H-ras is infrequent in bladder cancer: confirmation by single stranded conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res, 53, 133-9.
121. Kryger JV, Messing E (1996). Bladder cancer screening. Seminars Oncol 23: 585-97.
122. Kunze E, Chang-Claude J, Frentzel Beyme R (1992). Life style and occupational risk factors for bladder cancer in Germany: a case-control study. Cancer, 69, 1776-90.
123. Kunze E, Mohlmann R (1983). Proliferation-stimulating effect of phenacetin on the urothelium and papillary epithelium in rats. Urol Int, 38, 223-8.
124. La Vecchia CL, Negri E (1996) Nutrition and bladder cancer. Cancer Causes Control, 7, 95-100.
125. La Vecchia C, Negri E, D'Avanzo B, et al (1991). Genital and urinary tract diseases and bladder cancer. Cancer Res, 51, 629-31.
126. La Vecchia C, Negri E, Decarli A, et al (1989). Dietary factors in the risk of bladder cancer. Nutr Cancer, 12, 93-101.
127. Leaf CD, Wishnok JS, Tannenbaum SR (1989). Mechanisms of endogenous nitrosation. Cancer Surv, 8, 323-334.
128. Lee CCR, Fukushima S (1998). Alterations in cyclin D1, p53, and the cell cycle related elements: implications for distinct genetic pathways of urinary bladder carcinogenesis. Urol Oncol, 4, 58-72.
129. Lee CCR, Ichihara T, Yamamoto S, et al (1999). Reduced expression of the CDK inhibitor p27KIP1 in rat two-stage bladder carcinogenesis and its association with with expression profiles of p21WAF/Cip1 and p53. Carcinogenesis, 20, 1697-708.
130. Lee CCR, Yamamoto S, Morimura K, et al (1997a). Significance of cyclin D1 expression in trasnsitional cell carcinomas of the urinary bladder and its correlation with histopathological features. Cancer, 79, 780-9.
131. Lee CCR, Yamamoto S, Wanibuchi H, et al (1997b). Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Cancer Res, 57, 4765-76.
132. Levi F, Randimbison L, Te VC et al (1993). Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974-89. Br J Cancer, 67: 391-5.
133. Liaw KL, Linet MS, McLaughlin JK, et al (1997). Possible relation between hypertension and cancers of the renal pelvis and ureter. Int J Cancer, 70: 265-8.
134. Lina BAR, Woutersen RA (1989). Effects of urinary potassium and sodium ion concentrations and pH on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats. Carcinogenesis, 10, 1733-6.
135. Linet MS, Chow WH, McLaughlin JK, et al (1995). Analgesics and cancers of the renal pelvis and ureter. Int J Cancer, 62: 15-8.
136. Littlefield NA, Cueto C, Davis AK, Medlock K (1975). Chronic dose-response studies in mice fed 2-AAF. J Toxicol Environ Health, 1, 25-37.
137. Logothetic CJ, Xu HJ, Hu SX, et al (1992). Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst, 84, 1256-61.
138. Lower GM Jr (1982). Chemically induced human urinary bladder cancer. Cancer, 49, 1056-66.
139. Lucas SB (1982). Squamous cell carcinoma of the bladder and schistosomiasis. East Afr Med J, 59, 345-51.
140. Malik MOA, Veress B, Daoud EH, El-Hassan M (1975). Pattern of bladder cancer in the Sudan and its relation to schistosomiasis: a study of 255 vesicular carcinomas. J Trop Med Hyg, 78, 219-33.
141. WAF1/CIP1 mutations in superficial and invasive transitional carcinomas. Oncogene, 13, 1831-7.
142. Mann AM, Asamoto M, Masui T, et al (1994). Neu is not involved in N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamideinduced bladder carcinoma or 2-amino-4-(5-nitro-2-furyl)thiazole transformation of rat bladder epithelial cells. Cancer Lett., 84, 7-13.
143. Masui T, Don I, Takada N, et al (1994). p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 15, 2379-81.
144. Masui T, Mann AM, Macatee TL, et al (1992). Absence of ras oncogene activation in rat urinary bladder carcinomas induced by N-methyl-N-nitrosourea or N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 13, 2281-5.
145. Mathews-Roth MM, Lausen N, Drouin G, Richter A, Krinsky NI (1991). Effects of carotenoid administration on bladder cancer prevention. Oncology, 48, 177-9.
146. Matsui-Yuasa I, Otani S, Yano Y, et al (1992). Spermidine/spermine N1 acetyltransferase, a new biochemical marker for epithelial proliferation in rat bladder. Jpn J Cancer Res, 83, 1037-40.
147. McCarthy PV, Bhatia AJ, Saw SM, et al (1995). Cigarette smoking and bladder cancer in Washington County, Maryland: ammunition for health educators. Md Med J, 44, 1039-42.
148. McCredie M, Ford JM, Taylor JS, Stewart JH (1982). Analgesics and cancer of the renal pelvis in New South Wales. Cancer, 49, 2617-25.
149. McCredie M, Stewart JH, Carter JJ, Turner J, Mahoney JF (1986). Phenacetin and renal papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int, 30. 81-4.
150. Melick WF, Escue HM, Naryka JJ, Mezera RA, Wheeler EP (1955). The first reported cases of human bladder tumors due to a new carcinogen xenylamine. J Urol, 74, 760-6.
151. Mettlin C, Graham S (1979) Dietary risk factors in human bladder cancer. Am J Epidemiol, 110, 255-63.
152. Michaud DS. Spiegelman D. Clinton SK, et al (1999). Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst, 91, 605-13.
153. Mills PK, Beeson WL, Phillips RL, Frasen GE (1991). Bladder cancer in a low risk population: results from the Adventist Health Study. Am J Epidemiol, 133, 230-9.
154. Mizoguchi M, Naito H, Kurata Y, et al (1993). Influence of aging on multi-organ carcinogenesis in rats induced by Nmethyl-N-nitrosourea. Jpn J Cancer Res, 84, 139-146.
155. Momas I, Daures JP, Festy B, et al (1994a). Bladder cancer and black cigarette smoking. Some results from a French casecontrol study. Eur J Epidemiol, 10, 599-604.
156. Momas I, Daures JP, Festy B, et al (1994b). Relative importance of risk factors in bladder carcinogenesis: some new results about Mediterranean habits. Cancer Causes Control, 5, 326-32.
157. Moon RC, Kelloff GJ, Detrisac CJ, et al., 1993). Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis, 14, 1487-9.
158. Moore MA, Kunimoto T, Takasuka N, Park CB, Tsuda H (1999). European registry comparisons provide evidence of renal and colon as well as gallbladder cancer development. Eur J. Cancer Prev, 8, 137-46.
159. Mori S, Kurata Y, Takeuchi Y, et al (1987). Influences of strain and diet on the promoting effects of sodium L-ascorbate in two-stage urinary bladder carcinogenesis in rats. Cancer Res, 47, 3492-5.
160. Mori S, Hosono M, Machino S, et al (1994). Induction of renal pelvic and ureteral carcinomas by N-butyl-N-(4-hydroxybutyl)-nitrosamine in SD/cShi rats with spontaneous hydronephrosis. Toxicol Pathol, 22, 373-80.
161. Morimura K, Yamamoto S, Murai T, et al (1999). LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis. 20, 715-8
162. Morrison AS, Buring JE, Verhoek WG, et al (1984). An international study of smoking and bladder cancer. J Urol, 131, 650-4.
163. Mourah S, Cussenot O, Vimont V, et al.(1998) Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer, 79, 629-33.
164. Murai T, Mori S, Machino S, et al (1993). Induction of renal pelvic carcinoma by phenacetin in hydronephrosis-bearing rats of the SD/cShi strain. Cancer Res, 53, 4218-23.
165. Murasaki G, Zenser TV, Davis BB, Cohen SM (1984) Inhibition by aspirin of N-[4-(5-nitro-furyl)-2-thiazolyl]formamideinduced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis, 5, 53-5.
166. Nagata Y, Abe M, Kobayashi K, et al (1990). Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn J Cancer Res, 81, 22-7.
167. Nakanishi K, Fukushima S, Shibata M, et al (1978). Effects of phenacetin and caffeine on the urinary bladder of rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Gann, 69, 395-400.
168. Nakanishi K, Kurata Y, Oshima M, Fukushima S, Ito N (1982). Carcinogenicity of phenacetin: long-term feeding study in B6C3F1 mice. Int J Cancer, 29, 439-44.
169. Nakanowatari J, Fukushima S, Imaida K, Ito N, Nagase S (1988). Strain differences in N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis in rats. Jpn J Cancer Res, 79, 453-9.
170. Nishio Y, Kakizoe T, Ohtani M, et al (1986). L-isoleucine and L-leucine: tumor promoters of bladder cancer in rats. Science, 231, 843-5.
171. Nomura AM, Kolonel LN, Hankin JH, Yoshizawa CN (1991) Dietary factors in cancer of the lower urinary tract. Int J Cancer, 48, 199-205.
172. Ogasawara H, Imaida K, Ishiwata H, et al (1995) Urinary bladder carcinogenesis induced by melamine in F344 male rats: correlation between carcinogenicity and urolith formation. Carcinogenesis 16: 2773-7.
173. Ogawa K, Kimoto N, Asamoto, et al (2000). Aberrant expression of p27Kip1 is associated with malignant transformation of the rat bladder epithelium. Carcinogenesis, 21, 117-21.
174. Ohtani M, Fukushima S, Okamura T, et al (1984). Effects of intravesical instillation of antitumor chemotherapeutic agents on bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer, 54, 1525-9.
175. Okajima E, Denda A, Ozono S, et al (1998) Chemopreventive effects of nimesulide, a selective cyclooxygenase inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res, 58, 3028-3021.
176. Okajima E, Hiramatsu T, Hirao K, et al (1981). Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in dogs. Cancer Res, 41, 1958-66.
177. Okumura M, Shirai T, Tamano S, et al (1991). Uracil-induced calculi and carcinogenesis in the urinary bladder of rats treated simultaneously with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 12, 35-41.
178. Oyasu R, Hirao Y, Izumo K (1981). Enhancement by urine of urinary bladder carcinogenesis. Cancer Res, 41, 478-81.
179. Oyasu R, Iwasaki T, Matsumoto M, Hirao Y, Tabuchi Y (1978). Induction of tumors in heterotopic bladder by topical application of N-methyl-N-nitrosourea and N-butyl-N-(3-carboxypropyl)-nitrosamine. Cancer Res, 38, 3019-25.
180. Ozaki K, Sukata T, Yamamoto S, et al (1998). High susceptibility of p53(+/-) knockout mice to N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res, 58, 3806-11.
181. Ozaki M, Shibata MA, Takahashi S, et al (1997). Lack of involvement of p53 gene mutations in N-methyl-Nnitrosourea-induced bladder tumor progression in N-butyl-N-(4-hydroxybutyl)nitrosamine-treated rats and no suppression by indomethacin. Cancer Letters, 115, 249-55.
182. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. (1997) (Eds) Cancer Incidence in Five Continents Vol. VII. IARC Scientific Publications No 143., IARC, Lyon.
183. Patrianakos C, Hoffmann D (1979). Chemical studies of tobacco smoke. LXIV. On the analysis of aromatic amines in cigarette smoke. J Anal Chem, 3, 150-4.
184. Peluso M, Airoldi L, Armelle M, et al (1998). White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prevent, 7, 341-6.
185. Perucca, D., Szepetowski, P., Simon, M.-P, Gaudray P (1990). Molecular genetics of human bladder carcinomas. Cancer Genet Cytogenet, 49, 143-56.
186. Peters MMCG, Rivera MI, Jones TW, Monks TJ, Lau SS (1996). Glutathione conjugates of tert-butyl-hydroquinone, a metabolite of the urinary tract tumor promoter 3-tert-butylhydroxyanisole, are toxic to kidney and bladder. Cancer Res, 56, 1006-11.
187. Piper JM, Tonascia J, Matanoski GM (1986). Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Eng J Med, 313, 292-5.
188. Polsky MS, Weber CH Jr, Williams JE, et al (1976). Chronically infected and post-diversionary bladders: cytologic and histopathologic study. Urology, 7, 531-5.
189. Presti JCJ, Reuter VE, Galan T, Fair WR, Cordon-Cardo C (1991). Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res, 51, 5405-9.
190. Rao KVN, Detrisac CJ, Steele VE, et al (1996) Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17, 1435-8.
191. Riboli E, Gonzalez CA, Lopez-Abente G, et al (1991). Diet and bladder cancer in Spain: a multi-centre case-control study. Int J Cancer, 49, 214-9.
192. Risch HA, Bruch JD, Miller AB, et al (1992). Dietary factors and incidence of cancer of the urinary bladder. Am J Epidemiol, 127, 1179.
193. Romanenko A, Lee CCR, Yamamoto S, et al (1999). Urinary bladder lesions after the Chernobyl accident: immunohistochemical assessment of p53, proliferating cell nuclear antigen, cyclin D1 and p21WAF1/Cip1. Jpn J Cancer Res, 90, 144-153.
194. Romanenko A, Morimura K, Wanibuchi H, et al (submitted). Increased oxidative stress with gene alteration in urinary bladder epithelium after the Chernobyl accident. ?.
195. Rosenberg L, Rao RS, Palmer JR, et al (1998) Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 9: 83-8.
196. Rosin MP, Saad el Din Zaki S, Ward AJ, Anwar WA (1994). Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mut Res, 305: 283-92.
197. Rundo J, Mason J, Newton D, Taylor BT (1963). Biological half-life of cesium in man in acute and chronic exposure. Nature, 200, 188-9.
198. Saikawa S, Kanamaru H, Li B, Matsukawa S, Okada K (1996). Promoting effect of unilateral nephrectomy on urinary bladder carcinogenesis in rats. Jpn J Cancer Res 87: 1121-4.
199. Salim EI, Wanibuchi H, Morimura K, et al (2000). Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 21, (in press).
200. Schulte PA (1988). The role of genetic factors in bladder cancer. Cancer Detect Prev, 11, 379-88.
201. Shibata A, Ohneseit PF, Tsai YC, et al (1994). Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis, 15, 1085-7.
202. Shibata MA, Fukushima S, Asakawa E, Hirose M, Ito N (1992). The modifying effects of indomethacin or ascorbic acid on cell proliferation induced by different types of bladder tumor promoters in rat urinary bladder and forestomach mucosal epithelium. Jpn J Cancer Res, 83: 31-9.
203. Shibata MA, Hasegawa R, Shirai T, Takesada Y, Fukushima S (1993). Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int J Cancer, 55, 1011-7.
204. Shibata MA., Shirai T, Asakawa E, Hirose M, Fukushima S (1993). Inhibition by dehydroepiandrosterone of butylated hydroxyanisole (BHA) promotion of rat-bladder carcinogenesis and enhancement of BHA-induced forestomach hyperplasia. Int J Cancer, 53, 819-23.
205. Shibata MA, Shirai T, Ogawa K, et al (1994). DNA methylation adduct formation and H-ras gene mutations in progression of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tumors caused by a single exposure to N-methyl-Nnitrosourea. Carcinogenesis, 15, 2965-8.
206. Shimamura T, Takahashi S (1994). Reduced proliferation of cultured bladder cancer cells by indomethacin. New Jersey Med, 91, 532-4.
207. Shin YY, Kong G, Kim WS, et al (1997). Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer, 75, 1788-92.
208. Shirai T, Fradet Y, Huland H, et al (1995). The etiology of bladder cancer - are there any new clues or predictors of behaviour? Int J Urol, 2 (Suppl), 64-75.
209. Shirai T, Ikawa E, Fukushima S, Masui T, Ito N (1986). Uracilinduced urolithiasis and the development of reversible papillomatosis in the urinary bladder of F344 rats. Cancer Res, 46, 2062-7.
210. Shirai T, Tagawa Y, Fukushima S, Imaida K, Ito N (1987). Strong promoting activity of reversible uracil-induced urolithiasis on urinary bladder carcinogenesis in rats initiated with Nbutyl-N-(4-hydroxybutyl)nitorsamine. Cancer Res, 47, 6726-30.
211. Sidransky D, Von EA, Tsai YC, et al (1991). Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252, 706-9.
212. Silverman, DT, Hartge P, Morrison, AS, Devesa SS (1992) Epidemiology of bladder cancer. Haematol Oncol Clin North Am, 6, 1-30.
213. Slattery ML, West DW, Robinson LM (1988). Fluid intake and bladder cancer in Utah. Int J Cancer, 42, 17-22.
214. Spruck III, CH, Ohneseit, PF, Gonzalez, ZM, et al (1994). Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res, 54, 784-8.
215. Stein JP. Ginsberg DA. Grossfeld GD et al (1998). Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer [see comments]. J Natl Cancer Inst, 90, 1072-9.
216. Steineck G, Norell SE, Feychting M (1988). Diet, tobacco and urothelial cancer. A 14-year follow-up of 16,477 subjects. Acta Oncol, 27, 323-7.
217. Sturgeon SR, Hartge P, Silverman DT, et al (1994). Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology, 5, 218-25.
218. Sugimura T (1997). Overview of carcinogenic heterocyclic amines. Mutat Res, 376, 211-9.
219. Takahashi M, Toyoda K, Aze Y, et al (1993). The rat urinary bladder as a new target of heterocyclic amine carcinogenicity; Tumor induction by 3-amino-1-methyl-5Hpyridol(4,3-6)indol acetate. Jpn J Cancer Res, 84, 852-8.
220. Takayama S, Sieber SM, Adamson RH, et al (1998). Long-term feeding of sodium saccharin to nonhuman primates: implications for urinary tract cancer. J Natl Cancer Inst, 90, 19-25.
221. Tamano S, Asakawa E, Boomyaphiphat P, Masui T, Fukushima S (1993). Lack of promotion of N-butyl-N-(4-hydroxybutyl)nitrosamine-initiated urinary bladder carcinogenesis in mice by rat cancer promoters. Teratogenesis Carcinogenesis & Mutagenesis, 13, 89-96.
222. Tamano S, Fukushima S, Shirai T, Hirose M, Ito N (1987). Modification by -tocopherol, propyl gallate and teritary butylhydroquinone of urinary bladder carcinogenesis in Fischer 344 rats pretreated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Lett; 35:39-46.
223. Tamano S, Hagiwara A, Suzuki E, et al (1991). Time- and dosedependent induction of invasive urinary bladder cancers by N-ethyl-N-(4-hydroxybutyl)nitrosamine in B6C3F1 mice. Jpn J Cancer Res, 82, 650-6.
224. Tavani A. Fioretti F. La Vecchia C. Franceschi S (1998). Re: Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst, 90, 250-1.
225. Thon WF, Kliem V, Truss MC, et al (1995). Denovo urothelial carcinoma of the upper and lower urinary tract in kidneytransplant patients with end-stage analgesic nephropathy. World J Urol, 13, 254-61.
226. Toyoshima K, Leighton J (1975). Bladder calculi and urothelial hyperplasia with papillomatosis in the rat following insertion of chalk powder in the bladder cavity with subsequent trauma of the bladder wall. Cancer Res, 35, 3786-91.
227. Tricker AR (1996). Excretion of N-nitrosamines in patients with bacterial bladder infections or diversions of the urinary tract. Eur J Cancer Prev, 5 Suppl, 95-9.
228. Underwood M, Bartlett J, Reeves J, et al (1995). C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res, 55, 2422-30.
229. Utz DC Farrow GM (1984). Carcinoma in situ of the urinary tract. Urol Clin North Am, 11, 735-40.
230. Vena JE, Graham S, Freudenheim J, et al (1992). Diet in the epidemiology of bladder cancer in Western New York. Nutr Cancer, 18, 255-64.
231. Vena JE, Freudenheim J, Graham S, et al (1993). Coffee, cigarette smoking and bladder cancer in Western New York. Ann Epidemiol, 3, 586-91.
232. Vineis P, Simonato L (1986). Estimates for the proportions of bladder cancer attributable to occupation. Scand J Work Environ Health, 12, 55-60.
233. Vineis P, Terracini B (1990). Biochemical epidemiology of bladder cancer. Epidemiology, 1, 448-52.
234. Vizcaino AP, Parkin DM, Boffetta P, Skinner ME (1994). Bladder cancer: epidemiology and risk factors in Bulawyo, Zimbabwe. Cancer Causes Control, 7, 178-80.
235. Vozianov AF, Romanenko AM, Wester K, Busch C (1996). Long-term low-does irrdiation and urothelium in patients with chronic cystitis. J Acad Med Sci Ukraine, 2, 421-36.
236. Wallin H, Skipper PL, Tannenbaum ST, et al (1995). Altered aromatic amine metabolism in epileptic patients treated with phenobarbital. Cancer Epidemiol Biomarkers Prevent, 4, 771-3.
237. Wanibuchi H, Yamamoto S, Chen H, et al (1996). Promoting effects of dimethylarsinic acid on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in rats. Carcinogenesis, 17, 2435-9.
238. Wattenberg LW (1978). Inhibition of chemical carcinogenesis. J Natl Cancer Inst, 60, 11-8.
239. Wei M, Wanibuchi H, Yamamoto S, Li W, Fukushima S (1999). Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis, 20, 1873-6.
240. West RW, Beranek DT, Kadlubar FF (1983). Dose-dependent effects of dietary saccharin on promotion of urinary bladder carcinogenesis and on urothelial DNA adducts after initiation with N-methylnitrosourea. Adv Bladder Cancer Res, 2, 87-93.
241. Wolf H (1973). Studies on the role of tryptophan metabolites in the genesis of bladder cancer. Acta Clin Scand(suppl), 433,154-68.
242. Worth PHL (1971). Cyclophosphamide and the bladder. BMJ, 3, 182.
243. Wynder EL, Onderdonk J, Mantel N (1963). An epidemiological investigation of cancer of the bladder. Cancer, 16, 1388-407.
244. Yamamoto S, Chen T, Murai T, et al (1997a). Genetic instability and p53 mutations in metastatic foci of mouse urinary bladder carcinomans induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 18, 1877-82.
245. Yamamoto S, Konishi Y, Matsuda T, et al (1995a) Cancer induction by an organic compound, dimethylarsinic acid (cacodylic acid), in F344/DuCrj rats after pretreatment with five carcinogens. Cancer Res, 55, 1271-1276.
246. Yamamoto S, Masui T, Murai T, et al (1995b). Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 16, 2363-8.
247. Yamamoto S, Romanenko A, Wei M, et al (1999a). Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident. Cancer Res, 59, ?.
248. Yamamoto S, Wanibuchi H, Hori T, et al (1997b). Possible carcinogenic potential of dimethlarsinic acid as assessed in rat in vivo models: a review. Mutat Res, 386, 353-61.
249. Yamamoto S, Wei M, Lee CCR, et al (1999b). Enhancement of urinary bladder carcinogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Lett, 135, 137-44.
250. Youssef EM, Wanibuchi H, Mori S, et al (1999). Elevation of urinary enzyme levels in rat bladder carcinogenesis. Carcinogenesis, 20, 1247-52
251. Yu Y, Hu J, Wang PP, et al (1997). Risk factors for bladder cancer: a case-control study in northeast China [published erratum appears in Eur J Cancer Prev 1998 7, 171]. Eur J Cancer Prev, 6, 363-9.